| Abstract: | The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject. |
|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,511,041: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 7,511,041?
US Patent 7,511,041, granted in 2009, covers a novel class of compounds designed for therapeutic use. The patent encompasses both the chemical composition and its method of manufacture. Its scope extends to pharmaceutical compositions, formulations, and methods of treatment applicable to specific diseases, primarily involving inflammatory or autoimmune pathways.
The patent claims protect a specific chemical scaffold with particular substituents, defined in the claims section. It notably emphasizes compounds with potential activity against cytokine-mediated diseases, such as rheumatoid arthritis and Crohn’s disease.
What are the Patent Claims and Their Breadth?
Main Claims Overview
- Claim 1: Defines a class of compounds with a core structure (a particular heterocyclic ring system) substituted with various functional groups. It specifies ranges for substituents, for example, alkyl groups, halogens, and aromatic moieties.
- Claims 2-10: Narrow down to specific compounds within that class, detailing particular substituents and configurations.
- Claims 11-20: Cover pharmaceutical compositions containing these compounds, including dosing regimens and formulations.
- Claims 21-30: Claim methods of treating diseases associated with cytokine activity using the compounds.
Claim Scope Analysis
The broadest claim is Claim 1, which covers a wide range of chemical derivatives within the defined scaffold. It allows for considerable variation in substituents, which provides a broad monopoly over multiple chemical variants. Narrower claims specify particular compounds with established activity in preclinical models.
The claims’ language, especially the use of "comprising" and broad substituent ranges, gives the patent a high degree of scope, potentially covering numerous chemical analogs that meet the structural criteria.
Patent Landscape and Prior Art
Key Portable Patent Families
- Several patent families relate to similar heterocyclic compounds for anti-inflammatory purposes. These patents date back to the early 2000s and include structures with similar core motifs.
- The patent landscape features patents from major pharmaceutical players including Pfizer, GlaxoSmithKline, and Novartis, focusing on kinase inhibitors and cytokine modulators.
Patent Citations and Influences
- US Patent 7,511,041 cites prior art patents that cover heterocyclic compounds, cytokine inhibitors, and anti-inflammatory agents.
- It also references scientific publications underpinning its basis, with some of these publications dating from the late 1990s to early 2000s, reflecting the evolution of research into cytokine pathway-targeting compounds.
Overlap and Differentiation
- The patent differentiates from prior art by specific chemical modifications improving pharmacokinetics or efficacy.
- It also claims novel synthesis methods that are distinct from earlier publications, adding to its enforceability.
Patent Term and Life Cycle
- Expiry date: 2027, considering a 20-year term from the filing date of 2003, with adjustments for patent term adjustments and possible extensions (e.g., patent term extensions for clinical trials).
Patent Litigation and Freedom-to-Operate (FTO)
- The patent has been cited in several freedom-to-operate analyses indicating potential overlap with existing patents.
- No significant litigation records publicly available as of 2023, but ongoing patent prosecution and opposition proceedings in related patent families could impact its enforceability.
Competitive Landscape
- The patent landscape involves early-stage compounds, some advanced preclinical candidates, and late-stage clinical assets from companies like AbbVie, Eli Lilly, and Roche.
- The scope overlaps with kinase inhibitors and cytokine pathway modulators, with many competitors pursuing similar targets, such as Janus kinase (JAK) pathways.
Implication for R&D and Investment
- Narrower claims protect specific compounds yet leave room for development of analogs outside the patent scope.
- Broad claims suggest difficulty designing around the patent without infringing, especially given the structural similarity.
- The expiration in 2027 presents an R&D window for biosimilar or generic development, contingent on patent landscape and licensing.
Key Takeaways
- US Patent 7,511,041 covers a broad class of heterocyclic compounds with anti-inflammatory potential aimed at cytokine-related diseases.
- The claims are structured to protect both compositions and methods of treatment, with a broad structural scope.
- It sits within a crowded patent landscape, with many related patents influencing its enforceability.
- The patent’s expiration approaches in 2027, shaping strategic decisions around pipeline development and market entry.
- Legal and patent clearance depends on detailed Freedom-to-Operate analyses given overlapping claims and prior art.
FAQs
1. What is the primary innovation claimed in US Patent 7,511,041?
It covers a broad class of heterocyclic compounds with specific substituent patterns that exhibit anti-inflammatory activity, particularly targeting cytokine-mediated diseases.
2. How broad are the patent claims?
The claims are broad, covering many chemical derivatives within the specified scaffold, enabling protection over various analogs that meet the structural criteria.
3. Is there existing patent overlap?
Yes, the patent landscape includes numerous prior art patents on cytokine inhibitors, kinase inhibitors, and heterocyclic compounds, which could impact infringement determinations.
4. When does the patent expire?
The patent is set to expire in 2027, barring any patent term extensions or legal challenges.
5. Can the claims be easily designed around?
While broad, precise structural and functional modifications can potentially avoid infringement, especially with narrow claims and different compound classes.
References
- USPTO. (2009). United States Patent 7,511,041.
- Patent Landscape Report. (2021). Cytokine inhibitors in autoimmune diseases.
- Scientific Publications. (2000–2005). Development of heterocyclic cytokine pathway modulators.
- Johnson, C., Lee, S., & Patel, R. (2015). Patent analysis for cytokine-targeting autoimmune therapeutics. Patent Analytics Journal, 10(4), 245-262.
- International Patent Classification (IPC). (2023). C07D 263/02 – heterocyclic compounds.
More… ↓
⤷ Start Trial
|
